Phase II study of docetaxel and S-1 combination therapy in patients with previously treated non-small cell lung cancer

18122 Background: Docetaxel is active against chemotherapy-pretreated non-small-cell lung cancer (NSCLC). S-1 is a novel oral fluoropyrimidine, composed of tegafur, 5-chloro-2,4-dihydroxypyridine (...